In accordance with the decision at the Annual General Meeting of Oasmia Pharmaceutical AB on September 26, 2019, the two largest shareholders in terms of voting rights have chosen to participate in the Nomination Committee. Together with the Chairman of the Board they will constitute the Nomination Committee for the 2020 Annual General Meeting.
Per Arwidsson, Arwidsro, Chairman of the Nomination Committee
and Jörgen Olsson, Chairman of the Board
The Annual General Meeting for Oasmia will be held in Uppsala on Wednesday September 9, 2019. Shareholders who wish to submit proposals regarding the Board of Directors, the Chairman of the Board, remuneration for the Board, Chairman for the AGM or the Nomination Committee for the next Annual General Meeting can contact Oasmia’s Chairman via e-mail: firstname.lastname@example.org.
For further information, please contact
Investor Relations Oasmia
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm and Frankfurt Stock Exchange.